Review: Amiodarone reduces mortality after MI and for congestive heart failure


Question
Using individual patient data, what are the benefits and risks of amiodarone for patients who have congestive heart failure (CHF) or a history of myocardial infarction (MI)?

Data sources
Studies were identified through computerized databases and contact with authors and experts by the Amiodarone Trials Meta-Analysis Investigators (ATMAI).

Study selection
Randomized controlled trials comparing amiodarone with placebo or usual care in patients with CHF or a history of MI were selected.

Data extraction
Data were extracted on inclusion criteria, patient and disease characteristics, dose of amiodarone, type of control (placebo or usual care), duration of the study, and side effects. Main outcomes were all-cause mortality and arrhythmic or sudden death. Individual patient data were extracted or provided by trial investigators.

Main results
8 trials studied 5101 patients who had a history of MI, and 5 trials studied 1452 patients with CHF. All trials included a loading dose and a maintenance dose, both of which varied across studies. The combined mean follow-up was 1.4 years. The mean age of the patients was 61 years, 83% were men, 89% had a history of MI, 21% had nonischemic cardiomyopathy, 18% had diabetes, and 42% had ventricular tachycardia. The mean left ventricular ejection fraction was 31%. 29% of patients discontinued amiodarone early.

For all studies using intention-to-treat meta-analysis, the all-cause mortality rate was lower in the amiodarone group than in the control group (P = 0.03), as was the rate of arrhythmic or sudden death (P < 0.001) (Table). Heterogeneity was noted with differences in treatment effect among the individual trials. Subgroup analysis found no differences in benefit with amiodarone therapy among subgroups defined by sex, left ventricular ejection fraction, New York Heart Association class, age, ventricular premature depolarizations, or ventricular tachycardia.

Conclusion
Amiodarone leads to a modest reduction in all-cause mortality, death from arrhythmia, or sudden death in patients who have congestive heart failure or a history of myocardial infarction.

Source of funding: Sanofi, Paris, France.

For correspondence: Dr. S. J. Connolly, Hamilton Health Sciences Corporation, 231 Barton Street East, Hamilton, Ontario L8L 2X2, Canada. FAX 905-521-8820.

Review: Amiodarone reduces mortality after MI and for congestive heart failure

*Evid Based Med* 1998 3: 112
doi: 10.1136/ebm.1998.3.112

Updated information and services can be found at:
http://ebm.bmj.com/content/3/4/112.citation

These include:

**References**
This article cites 1 articles, 0 of which you can access for free at:
http://ebm.bmj.com/content/3/4/112.citation#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/